{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:43Z","timestamp":1793016403643,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T00:00:00Z","timestamp":1541203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Joint Scientific Special foundation of Guangdong Provincial Department of Science and Technology-Academy of Traditional Chinese Medicine","award":["2013A032500017"],"award-info":[{"award-number":["2013A032500017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13000-018-0763-3","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T07:20:18Z","timestamp":1541229618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["MYO18B promotes hepatocellular carcinoma progression by activating PI3K\/AKT\/mTOR signaling pathway"],"prefix":"10.1186","volume":"13","author":[{"given":"Zhenyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,3]]},"reference":[{"issue":"2","key":"763_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"Jorge A. Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin C, et al. Diagnosis, staging and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018. \n                    https:\/\/doi.org\/10.1002\/hep.29913\n                    \n                  .","journal-title":"Hepatology"},{"issue":"5","key":"763_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","volume":"28","author":"C Bosetti","year":"2014","unstructured":"Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753\u201370.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"763_CR3","doi-asserted-by":"publisher","first-page":"e000042","DOI":"10.1136\/esmoopen-2016-000042","volume":"1","author":"M Pinter","year":"2016","unstructured":"Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1(2):e000042.","journal-title":"ESMO Open"},{"issue":"5","key":"763_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1055-9965.EPI-11-1005","volume":"21","author":"AG Singal","year":"2012","unstructured":"Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21(5):793\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10127","key":"763_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet"},{"issue":"1","key":"763_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2014.09.002","volume":"19","author":"LM Kulik","year":"2015","unstructured":"Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19(1):23\u201343.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"763_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/138920211795564359","volume":"12","author":"N Nishida","year":"2011","unstructured":"Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics. 2011;12(2):130\u20137.","journal-title":"Curr Genomics"},{"issue":"41","key":"763_CR8","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.3748\/wjg.v22.i41.9069","volume":"22","author":"ZS Niu","year":"2016","unstructured":"Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: an update. World J Gastroenterol. 2016;22(41):9069\u201395.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"763_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3748\/wjg.v12.i8.1175","volume":"12","author":"L Zhou","year":"2006","unstructured":"Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(8):1175\u201381.","journal-title":"World J Gastroenterol"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13000-015-0371-4","volume":"10","author":"H Ajdarkosh","year":"2015","unstructured":"Ajdarkosh H, Dadpay M, Yahaghi E, et al. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues. Diagn Pathol. 2015;10:135.","journal-title":"Diagn Pathol"},{"issue":"11","key":"763_CR11","doi-asserted-by":"publisher","first-page":"e5811","DOI":"10.1097\/MD.0000000000005811","volume":"96","author":"SJ Park","year":"2017","unstructured":"Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96(11):e5811.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"763_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cgh.2013.10.038","volume":"13","author":"R Chaiteerakij","year":"2015","unstructured":"Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2015;13(2):237\u201345.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"763_CR13","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752\u201363.","journal-title":"Gastroenterology"},{"issue":"2","key":"763_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3892\/or.2016.4842","volume":"36","author":"P Reichl","year":"2016","unstructured":"Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians (review). Oncol Rep. 2016;36(2):613\u201325.","journal-title":"Oncol Rep"},{"issue":"1","key":"763_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","volume":"137","author":"JA Marrero","year":"2009","unstructured":"Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110\u20138.","journal-title":"Gastroenterology"},{"issue":"5","key":"763_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/hep.1840170508","volume":"17","author":"K Takahashi","year":"1993","unstructured":"Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology. 1993;17(5):794\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"763_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1022>3.0.CO;2-V","volume":"29","author":"XY Guan","year":"2000","unstructured":"Guan XY, Fang Y, Sham JS, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2000;29(2):110\u20136.","journal-title":"Genes Chromosomes Cancer."},{"issue":"13","key":"763_CR18","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3748\/wjg.v10.i13.1975","volume":"10","author":"GN Zhu","year":"2004","unstructured":"Zhu GN, Zuo L, Zhou Q, et al. Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. World J Gastroenterol. 2004;10(13):1975\u20138.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"763_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/gcc.20027","volume":"40","author":"M Tani","year":"2004","unstructured":"Tani M, Ito J, Nishioka M, et al. Correlation between histone acetylation and expression of the MYO18B gene in human lung cancer cells. Genes Chromosomes Cancer. 2004;40(2):146\u201351.","journal-title":"Genes Chromosomes Cancer."},{"issue":"19","key":"763_CR20","doi-asserted-by":"publisher","first-page":"12269","DOI":"10.1073\/pnas.192445899","volume":"99","author":"M Nishioka","year":"2002","unstructured":"Nishioka M, Kohno T, Tani M, et al. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci U S A. 2002;99(19):12269\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"763_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/gcc.20180","volume":"43","author":"T Nakano","year":"2005","unstructured":"Nakano T, Tani M, Nishioka M, et al. Genetic and epigenetic alterations of the candidate tumor-suppressor gene MYO18B, on chromosome arm 22q, in colorectal cancer. Genes Chromosomes Cancer. 2005;43(2):162\u201371.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"763_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ijc.20339","volume":"112","author":"N Yanaihara","year":"2004","unstructured":"Yanaihara N, Nishioka M, Kohno T, et al. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. Int J Cancer. 2004;112(1):150\u20134.","journal-title":"Int J Cancer"},{"issue":"1","key":"763_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"10","key":"763_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2217\/fon.11.95","volume":"7","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Lui VW, Yeo W. Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7(10):1149\u201367.","journal-title":"Future Oncol"},{"issue":"1","key":"763_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0022-2836(02)01335-9","volume":"326","author":"M Salamon","year":"2003","unstructured":"Salamon M, Millino C, Raffaello A, et al. Human MYO18B, a novel unconventional myosin heavy chain expressed in striated muscles moves into the myonuclei upon differentiation. J Mol Biol. 2003;326(1):137\u201349.","journal-title":"J Mol Biol"},{"issue":"3","key":"763_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bbrc.2006.02.025","volume":"342","author":"T Inoue","year":"2006","unstructured":"Inoue T, Kon T, Ajima R, et al. MYO18B interacts with the proteasomal subunit Sug1 and is degraded by the ubiquitin-proteasome pathway. Biochem Biophys Res Commun. 2006;342(3):829\u201334.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"763_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1349-7006.2004.tb02203.x","volume":"95","author":"J Yokota","year":"2004","unstructured":"Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004;95(3):197\u2013204.","journal-title":"Cancer Sci"},{"issue":"5","key":"763_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3727\/000000006783981062","volume":"16","author":"N Edakuni","year":"2006","unstructured":"Edakuni N, Ikuta K, Yano S, et al. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Oncol Res. 2006;16(5):235\u201343.","journal-title":"Oncol Res"},{"issue":"9","key":"763_CR29","doi-asserted-by":"publisher","first-page":"21138","DOI":"10.3390\/ijms160921138","volume":"16","author":"S Faes","year":"2015","unstructured":"Faes S, Dormond O. PI3K and AKT: unfaithful Partners in Cancer. Int J Mol Sci. 2015;16(9):21138\u201352.","journal-title":"Int J Mol Sci"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR signaling in Cancer. Front Oncol. 2014;4:64.","journal-title":"Front Oncol"},{"issue":"7","key":"763_CR31","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/C5MB00101C","volume":"11","author":"T Ersahin","year":"2015","unstructured":"Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K\/AKT\/mTOR interactive pathway. Mol BioSyst. 2015;11(7):1946\u201354.","journal-title":"Mol BioSyst"},{"issue":"56","key":"763_CR32","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/sj.onc.1207115","volume":"22","author":"TF Franke","year":"2003","unstructured":"Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K\/Akt and apoptosis: size matters. Oncogene. 2003;22(56):8983\u201398.","journal-title":"Oncogene"},{"issue":"34","key":"763_CR33","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853\u20137.","journal-title":"Oncogene"},{"issue":"2","key":"763_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther. 2014;142(2):164\u201375.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"763_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9\u201322.","journal-title":"Cancer Cell"},{"issue":"4","key":"763_CR36","first-page":"713","volume":"20","author":"W Li","year":"2008","unstructured":"Li W, Tan D, Zhang Z, Liang JJ, Brown RE. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep. 2008;20(4):713\u20139.","journal-title":"Oncol Rep"},{"issue":"102","key":"763_CR37","first-page":"7","volume":"19","author":"L Ma","year":"2015","unstructured":"Ma L, Ji L, Yu Y, Wang J. Novel molecular targets for diagnosis and treatment of hepatocellular carcinoma. Discov Med. 2015;19(102):7\u201314.","journal-title":"Discov Med"},{"issue":"8","key":"763_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","volume":"16","author":"D Morgensztern","year":"2005","unstructured":"Morgensztern D, McLeod HL. PI3K\/Akt\/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs. 2005;16(8):797\u2013803.","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"763_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.coph.2008.08.004","volume":"8","author":"TA Yap","year":"2008","unstructured":"Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8(4):393\u2013412.","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"763_CR40","first-page":"749","volume":"1","author":"V Papadimitrakopoulou","year":"2006","unstructured":"Papadimitrakopoulou V, Adjei AA. The Akt\/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol. 2006;1(7):749\u201351.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"763_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1078-0432.CCR-14-3239","volume":"22","author":"AM Eiden","year":"2016","unstructured":"Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA. Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in Cancer therapy. Clin Cancer Res. 2016;22(2):277\u201383.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"763_CR42","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","volume":"15","author":"S Mabuchi","year":"2009","unstructured":"Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009;15(17):5404\u201313.","journal-title":"Clin Cancer Res"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-018-0763-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T00:12:15Z","timestamp":1572739935000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-018-0763-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1186\/s13000-018-0763-3","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,3]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The procedure was reviewed and approved by the ethics committee of Shantou University. Human tissue acquisition and usage in this study complied with the National Regulations on the Use of Clinical Samples in China. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"85"}}